Agilent Expands Line of Innovative Flow Cytometers with the NovoCyte Penteon
September 17 2020 - 8:00AM
Business Wire
Providing unmatched sensitivity, resolution, speed, and
flexibility of colors
Agilent Technologies Inc. (NYSE: A) today announced the launch
of the Agilent NovoCyte Penteon, a sensitive flow cytometer with
five lasers and up to 30 fluorescence channels. The NovoCyte
Penteon provides excellent sensitivity, resolution, speed, and
flexibility. It has a large dynamic range of 7.2 log, along with
fully automated compensation features, enabling users to pick up
both dim and bright signals in the same run.
“The NovoCyte Penteon provides expanded capabilities of UV laser
excitation that accommodate multicolor flow cytometry assays which
are becoming increasingly sophisticated,” stated Xiaobo Wang,
Ph.D., who joined Agilent from ACEA, as general manager of the Flow
Cytometry and Real-Time Cell Analysis Business. “The NovoCyte
Penteon is continuing the NovoCyte legacy of great cytometry
performance matched with intuitiveness and simplicity of user
experience.”
“NovoCyte Penteon is expanding Agilent’s offering of advanced
flow cytometer instrumentation,” stated Todd Christian, vice
president, and general manager of Agilent's Cell Analysis Division.
“Agilent is committed to continuing our innovation for trusted cell
analysis solutions, to support scientists of the world in their
endeavor of scientific and therapeutic discovery for advancing the
human condition.”
The resolution easily discerns particles in the range of 100
nanometers, and the precision fluidics are considered to be among
the best on the market. Coupled with the power of the highly
intuitive NovoExpress software package, the system can be fully
automated and is easy to use, providing an exceptional user
experience in data acquisition, analysis, and reporting.
The product line is an innovative breakthrough in flow
cytometry. It capitalizes on the global success of the Agilent line
of flow cytometers, including the NovoCyte, the NovoCyte Quanteon,
and the NovoCyte Advanteon.
Flow cytometry technology is integral to basic research, drug
discovery, and clinical diagnostics. Currently, a major trend in
flow cytometry is to measure more parameters simultaneously,
especially useful in monitoring for certain blood disorders and in
the field of immuno-oncology.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life
sciences, diagnostics, and applied chemical markets. Now in its
20th year as an independent company delivering insight and
innovation toward improving the quality of life, Agilent
instruments, software, services, solutions, and people provide
trusted answers to customers' most challenging questions. The
company generated revenue of $5.16 billion in fiscal 2019 and
employs 16,300 people worldwide. Information about Agilent is
available at www.agilent.com. To receive the latest Agilent news,
subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn,
Twitter, and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200917005191/en/
Media Contact Naomi Goumillout +1.781.266.2819
naomi.goumillout@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Sep 2023 to Sep 2024